Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin specific protease 11 (USP11) is a cysteine protease enzyme that functions as a deubiquitinase, specifically removing ubiquitin from proteins to regulate their stability, localization, and activity[1][2][3][4]. USP11 is involved in key cellular processes including DNA damage repair, cell cycle control, and chromatin remodeling by deubiquitinating target proteins such as histone H2A, histone H2B, BRCA2, PALB2, p21, and XPC[3][4]. It plays a pivotal role in genomic stability, cell survival, and response to genotoxic stress. Dysregulation or overexpression of USP11 has been implicated in several cancers, where it may promote tumor progression or serve as a prognostic biomarker, especially in ERα-positive breast cancer[5]. USP11 is therefore considered a promising therapeutic target in oncology and potentially other diseases involving altered protein ubiquitination[4].
Inhibition of deubiquitinase activity leads to impaired DNA repair and altered cell proliferation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin specific protease 11 (USP11).